At the same time, reducing immunosuppression in the tumor microenvironment, achieved through VEGF inhibition, enhances the effectiveness of immune checkpoint inhibitors such as anti-PD-1/PD-L1 and anti-CTLA-4 [219]. The gene discussed is VEGFA; the disease is neoplasm.